hotspot -WSS

hotspot

author：hotspot 2025-09-06 02:16:27 - browse：933

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Covid isolation guidance eased by the CDC

hotspot

WSS

Psilocybin's anti

What do new weight loss drugs mean for bariatric surgery?

Departing Stanford president retracts two papers

AstraZeneca bets AAV gene therapy will still deliver the goods

Medicare explains how it will choose drugs for negotiation

Biotech companies concerned about China biosecurity crackdown

leisure time

hotspot

Bluebird and the case for gene therapy profits

focus

Virginia high school admissions case could be legal follow

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

DIEP, the 'gold standard' of breast reconstruction, is under threat

AstraZeneca loses challenge to Medicare drug price negotiation

Trump demands the U.S. pay no more for drugs than other countries … again

ALS groups 'won't be played again' by the FDA, drug sponsors

BioMarin wins approval for gene therapy to treat hemophilia A

Biotech companies concerned about China biosecurity crackdown

Moonlake's readout produced a cash windfall. Risks remain

Australia’s approach to dialysis celebrates life

entertainment

Neuroscience startup Neumora files for IPO

AstraZeneca loses challenge to Medicare drug price negotiation

Biotech companies concerned about China biosecurity crackdown

Apellis safety probe of eye disease drug centers on injection needle

Appeals court upholds limits to abortion pill

Medicare explains how it will choose drugs for negotiation

hotspot

hotspot

hotspot

entertainment